Vaxcyte Inc (NASDAQ:PCVX) is among the best 52-week high US stocks to buy. Vaxcyte Inc (NASDAQ:PCVX) has completed enrollment in a pair of Phase 3 clinical trials evaluating its vaccine candidate VAX-31. The company announced this development on March 23, stating that it enrolled approximately 4,000 participants in the OPUS-1 trial and 1,300 in the OPUS-2 trial.
M. A. Arkhipov/Shutterstock.com
Vaxcyte’s vaccine candidate VAX-31 is intended to prevent invasive pneumococcal disease and pneumonia in adults. It’s also being tested in infants. The two Phase 3 trials that have completed enrollment are focused on adults.
In the OPUS-1 trial, VAX-31’s safety, tolerability, and immune response will be evaluated against two current standard pneumococcal vaccines. This study has two cohorts. It includes adults aged 50 years and older, and a separate group of adults aged 18 – 49 years. This study is being conducted at around 50 sites across the US, and its topline results are expected in Q4 2026.
The OPUS-2 trial will also evaluate the safety, tolerability, and immune response of VAX-31 in adults aged 50 and older. But in this study, they are assessing VAX-31 when administered alongside a licensed seasonal influenza vaccine. This is meant to be a descriptive study, and Vaxcyte said the results will inform a potential post-licensure outcomes study. The company is running the OPUS-2 trial at 25 sites across the US, and results are expected out in the first half of 2027.
At the end of 2025, Vaxcyte had $2.4 billion in cash. Then on February 24, the management disclosed that they had raised an additional $600 million in cash through equity financing to strengthen the company’s balance sheet and extend its cash runway.
Vaxcyte Inc (NASDAQ:PCVX), based in California, is a biotech company focused on developing advanced vaccines. It aims to offer solutions to prevent or treat bacterial diseases such as pneumonia. The company has several potential drugs in various development stages, with its most advanced drug candidates in Phase 3 trial stage.
While we acknowledge the risk and potential of PCVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCVX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 9 Must-Buy Penny Stocks to Invest In Now and 10 Best AI Stocks to Buy Under $25.
Disclosure: None. Follow Insider Monkey on Google News.
